Nothing Special   »   [go: up one dir, main page]

BR112021019643A2 - Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos - Google Patents

Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos

Info

Publication number
BR112021019643A2
BR112021019643A2 BR112021019643A BR112021019643A BR112021019643A2 BR 112021019643 A2 BR112021019643 A2 BR 112021019643A2 BR 112021019643 A BR112021019643 A BR 112021019643A BR 112021019643 A BR112021019643 A BR 112021019643A BR 112021019643 A2 BR112021019643 A2 BR 112021019643A2
Authority
BR
Brazil
Prior art keywords
pyrazolopyridine compounds
ret inhibitors
ret
pyrazolopyridine
compounds
Prior art date
Application number
BR112021019643A
Other languages
English (en)
Inventor
Bao Yingxia
Chen Shuhui
Chen Zhengxia
Dai Meibi
Luo Zhibo
Wang Jiansong
Wang Wei
Xie Zhoufan
Zhang Yang
Original Assignee
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Baiyunshan Pharmaceutical General Factory
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Baiyunshan Pharmaceutical General Factory, Medshine Discovery Inc filed Critical Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Baiyunshan Pharmaceutical General Factory
Publication of BR112021019643A2 publication Critical patent/BR112021019643A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

compostos de pirazolopiridina como inibidores do ret e uso dos mesmos. é revelada uma série de compostos de pirazolopiridina e uso dos mesmos na preparação de um inibidor de quinase do ret. especificamente, é revelado um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo.
BR112021019643A 2019-04-03 2020-04-03 Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos BR112021019643A2 (pt)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
CN201910270289 2019-04-03
CN201910449875 2019-05-27
CN201910449629 2019-05-27
CN201910484977 2019-06-04
CN201910892976 2019-09-20
CN201910892514 2019-09-20
CN201910893692 2019-09-20
CN201911086217 2019-11-08
CN201911105397 2019-11-13
CN201911110201 2019-11-13
CN202010023277 2020-01-09
PCT/CN2020/083318 WO2020200316A1 (zh) 2019-04-03 2020-04-03 作为ret抑制剂的吡唑并吡啶类化合物及其应用

Publications (1)

Publication Number Publication Date
BR112021019643A2 true BR112021019643A2 (pt) 2021-12-07

Family

ID=72664966

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019643A BR112021019643A2 (pt) 2019-04-03 2020-04-03 Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos

Country Status (6)

Country Link
US (1) US20220220104A1 (pt)
EP (1) EP3950685A4 (pt)
JP (1) JP7291243B2 (pt)
CN (1) CN113474343B (pt)
BR (1) BR112021019643A2 (pt)
WO (1) WO2020200316A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020228756A1 (zh) * 2019-05-14 2020-11-19 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
JP7318097B2 (ja) * 2019-07-12 2023-07-31 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド Ｒｅｔ選択的阻害剤、その製造方法および用途
WO2021088911A1 (zh) * 2019-11-08 2021-05-14 杭州邦顺制药有限公司 作为ret激酶抑制剂的3、6二氮杂双环[3.1.1]庚烷衍生物
CN112851664B (zh) * 2019-11-12 2024-03-29 浙江海正药业股份有限公司 吡唑[1,5-a]吡啶-3-腈化合物及其在医药上的用途
CN112939967B (zh) * 2019-12-11 2024-08-27 深圳众格生物科技有限公司 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
AU2020410900B2 (en) * 2019-12-27 2024-06-13 Tyk Medicines, Inc. Compound used as RET kinase inhibitor and application thereof
AU2021326917B2 (en) * 2020-08-20 2024-08-29 Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. Heteroaromatic ring compound as ret kinase inhibitor, and preparation and use thereof
CN115867273A (zh) * 2020-09-29 2023-03-28 广州白云山医药集团股份有限公司白云山制药总厂 吡啶并吡唑类化合物的晶型及其制备方法
CA3198559A1 (en) * 2020-11-13 2022-05-19 Hua Dong Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form
CN112679494B (zh) * 2020-12-24 2023-05-16 贵州民族大学 一种吡唑并[1,5-a]吡啶衍生物的制备方法
CN113816955B (zh) * 2021-09-29 2022-08-26 厦门云凡医药科技有限公司 一种ret激酶抑制剂中间体及其制备方法
WO2024030968A1 (en) * 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180041135A (ko) 2015-07-16 2018-04-23 어레이 바이오파마 인크. Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물
DK3442980T3 (da) * 2016-04-15 2021-08-30 Cancer Research Tech Ltd Heterocykliske forbindelser som ret-kinase-hæmmere
JP7201586B6 (ja) 2016-09-08 2024-02-08 サビラ バイオサイエンシズ エルエルシー 神経保護作用、自己免疫性ならびに癌の疾患および病状において有用な１，２－ジチオラン化合物
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111285886B (zh) 2018-12-06 2023-04-11 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
AU2019392232A1 (en) 2018-12-07 2021-05-20 Sunshine Lake Pharma Co., Ltd. RET inhibitors, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
EP3950685A4 (en) 2022-12-14
US20220220104A1 (en) 2022-07-14
CN113474343A (zh) 2021-10-01
JP2022529209A (ja) 2022-06-20
CN113474343B (zh) 2024-01-23
JP7291243B2 (ja) 2023-06-14
WO2020200316A1 (zh) 2020-10-08
EP3950685A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
BR112021019643A2 (pt) Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201792116A1 (ru) Ингибитор янус-киназы
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201690752A1 (ru) Ингибиторы g12c kras
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
TN2017000374A1 (en) TGF-β INHIBITORS
EA201991884A2 (ru) Ингибиторы g12c kras
EA201590674A1 (ru) Производные 5-фенокси-3h-пиримидин-4-она и их применение в качестве ингибиторов обратной транскрипазы вич
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA202193015A1 (ru) Ингибиторы cdk
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
PH12016502353A1 (en) Pharmaceutical composition
BR112016028814A2 (pt) ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo?
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
TW201613577A (en) Pharmaceutical combinations
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
BR112019008415A2 (pt) composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]